AstraZeneca Expands Rare Disease Portfolio with $1.05 Billion Amolyt Acquisition
Felicia Rodriguez
March 14, 2024
AstraZeneca’s acquisition of Amolyt Pharma for $1.05 billion is a big step toward growing its rare disease portfolio. Amolyt Pharma, a French biotech business, focuses on finding medicines for uncommon endocrine illnesses. This acquisition is consistent with AstraZeneca’s strategic objective of expanding its portfolio and